Biomerica (BMRA) vs Trinity Biotech (TRIB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biomerica is the larger company by market cap ($8.7 million vs $4.9 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRA | TRIB |
|---|---|---|
| Share price | $1.89 | $6.04 |
| Market cap | $8.69M | $4.91M |
| 1-day change | -0.53% | -10.91% |
| YTD return | -25.00% | — |
| 1-year return | -34.38% | — |
| 5-year return | -95.74% | — |
| Forward P/E | 4.85 | — |
| EPS (TTM) | $-1.30 | $-60.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.21 | $52.50 |
| 52-week low | $1.45 | $5.01 |
| Distance from 52-week high | -41.12% | -88.50% |
| Average volume | 70.88K | 21.66K |
| Shares outstanding | 4.60M | 813.13K |
| Employees | 50 | 287 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biomerica
BMRA stock →Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels.
Healthcare · Medical Devices · 50 employees
About Trinity Biotech
TRIB stock →Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Healthcare · Medical Devices · 287 employees
BMRA vs TRIB FAQ
Which is bigger, Biomerica or Trinity Biotech?
Biomerica (BMRA) is larger, with a market capitalization of $8.69M compared with $4.91M for Trinity Biotech (TRIB).
Are Biomerica and Trinity Biotech in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.